Approval · Notice of Compliance 2571 · 2001
SEREVENT: Notice of Compliance 2571
Issued August 27, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2571
- Date
- August 27, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in manufacturer name
- Therapeutic class
- Bronchodilator (beta2-adrenergic stimulant)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SEREVENT | 02211742 | Cancelled Post Market |
| SEREVENT DISKHALER DISK | 02214261 | Cancelled Post Market |
| SEREVENT DISKUS | 02231129 | Marketed |
Medicinal ingredients
- SALMETEROL XINAFOATE 25 MCG per ACT
- SALMETEROL XINAFOATE 50 MCG per DOSE